A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: A phase II pilot study

Claudio Dazzi, A. Cariello, M. Giannini, M. Del Duca, P. Giovanis, G. Fiorentini, M. Leoni, G. Rosti, D. Turci, A. Tienghi, B. Vertogen, F. Zumaglini, U. De Giorgi, M. Marangolo

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The purpose of our study was to evaluate the activity and toxicity of a sequential chemo-radiotherapeutic treatment on the basis of an earlier report by The Johns Hopkins Oncology Center. Materials and methods: Eighteen patients with histologically diagnosed malignant gliomas entered the study. Fifteen patients had glioblastoma multiforme (83%). BCNU (40 mg/sqm/die) and Cisplatin (40 mg/sqm/die) were administered concurrently for 3 days every 3-4 weeks. Radiotherapy consisted of 45 Gy whole cranial irradiation plus a 15 Gy boost on the preoperative volume. Results: Thirteen patients had measurable disease and were evaluable for response. After chemotherapy we obtained 3 CRs (complete remission) and 4 PRs (partial remission) (RR (response rate 54%). Three PRs were converted to CRs after radiotherapy, for a complete remission rate of 46% (6/13). The median duration of response was 10 months. The median survival of the entire patients population was 9 months with 33% survival rates at 1 year. Hematological toxicity grade 4 in one patient and grade 3 in two patients were the major complications due to chemotherapy. Conclusions: Our sequential chemo-radiotherapeutic regimen appears to have significant activity in adults with newly, diagnosed high-grade gliomas.

Original languageEnglish
Pages (from-to)515-518
Number of pages4
JournalAnticancer Research
Volume20
Issue number1 B
Publication statusPublished - 2000

Keywords

  • Chemotherapy
  • Malignant glioma
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: A phase II pilot study'. Together they form a unique fingerprint.

Cite this